about
PCR diagnostics and monitoring of adenoviral infections in hematopoietic stem cell transplantation recipientsCriteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia.The genetic tumor background is an important determinant for heterogeneous MYCN-amplified neuroblastoma.Allogeneic stem cell transplantation for patients with advanced rhabdomyosarcoma: a retrospective assessment.Impact of Disseminated Neuroblastoma Cells on the Identification of the Relapse-Seeding CloneSignificant changes in the composition of the precursor B-cell compartment in children less than 2 years old.Detection of Polish clinical Aspergillus fumigatus isolates resistant to triazoles.Effective treatment of cytomegalovirus retinitis and neuritis with retrobulbar ganciclovir after treosulfan-based autologous bone marrow transplant.Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents.Treosulfan-based conditioning regimen in a second matched unrelated peripheral blood stem cell transplantation for a pediatric patient with CGD and invasive aspergillosis, who experienced initial graft failure after RIC.Posttransplant adoptive immunotherapy with interleukin-2 in children suffering from neuroectodermal tumors with poor prognosis.RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia.Imatinib in the treatment of chronic myeloid leukemia in children and adolescents is effective and well tolerated: Report of the Polish Pediatric Study Group for the Treatment of Leukemias and Lymphomas.Solid Cancers in the Premature and the Newborn: Report of Three National Referral Centers.The Formation of Blood Vessel After the Administration of the Plasmid Encoding Ang-1 Gene in Fischer Rats.Consolidation of first-line therapy with busulphan and melphalan, and autologous stem cell rescue in children with Ewing's sarcoma.Donor lymphocyte infusions in adolescents and young adults for control of advanced pediatric sarcoma.Comprehensive Investigation of miRNome Identifies Novel Candidate miRNA-mRNA Interactions Implicated in T-Cell Acute Lymphoblastic LeukemiaImmunologic effects of intermediate-dose IL-2 i.v. after autologous hematopoietic cell transplantation in pediatric solid tumorsImmune reconstitution after haematopoietic cell transplantation in children: immunophenotype analysis with regard to factors affecting the speed of recovery[Megachemotherapy and autologous hematopoietic stem cell transplantation in children with solid tumours excluding neuroblastoma--experience of Polish paediatric centres]Allogeneic hematopoietic cell transplantation from alternative donors in children with myelodysplastic syndrome: is that an alternative?[Treatment results of children with neuroblastoma: report of Polish Pediatric Solid Tumor Group]Higher CD34(+) and CD3(+) cell doses in the graft promote long-term survival, and have no impact on the incidence of severe acute or chronic graft-versus-host disease after in vivo T cell-depleted unrelated donor hematopoietic stem cell transplantatIncidence, course, and outcome of Clostridium difficile infection in children with hematological malignancies or undergoing hematopoietic stem cell transplantationAnalysis of the rRNA methylation complex components in pediatric B-cell precursor acute lymphoblastic leukemia: A pilot studyVeno-occlusive disease in children and adolescents after hematopoietic stem cell transplantation: Did the Modified Seattle Criteria fit the characteristics of pediatric population?Feasibility and Safety of Treosulfan, Melphalan, and Thiotepa-Based Megachemotherapy with Autologous or Allogeneic Stem Cell Transplantation in Heavily Pretreated Children with Relapsed or Refractory NeuroblastomaSafety and efficacy of autologous mononuclear cell and stem cell apheresis in very low-weight children-Experience at a single centerPediatric unmanipulated haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide and reduced intensity, TBI-free conditioning regimens in salvage transplantationsPremature cyclosporine cessation and TBI-containing conditioning regimen increase the risk of acute GvHD in children undergoing unrelated donor hematopoietic stem cell transplantationEltrombopag Therapy in Children With Rare Disorders Associated With ThrombocytopeniaAllogeneic Stem Cell Transplantation after Fanconi Anemia Conditioning in Children with Ataxia-Telangiectasia Results in Stable T Cell Engraftment and Lack of Infections despite Mixed ChimerismSynonymous GATA2 mutations result in selective loss of mutated RNA and are common in patients with GATA2 deficiencyFactors affecting survival in children requiring intensive care after hematopoietic stem cell transplantation. A retrospective single-center study
P50
Q34316584-ADCEE6C4-CF40-4CC3-920D-1C58C25FC80FQ34797988-93564655-132E-4D1B-AD54-D4A9D9AEFC4AQ37105296-D2F30286-3CCF-4E6C-86BC-6E2FBAB82123Q37323038-143697CF-9E4F-4431-BC8A-C4BFFD305216Q38947597-C589E6B4-35F5-4DC7-8570-2478DBBC7587Q39454415-0C72955B-1CC1-4C82-8E45-6860BD2F9C77Q40279616-31A00B1A-7734-48EE-B98B-79A492D3B754Q40882187-4374F0DC-E2CD-4C0D-85CA-DCA15BBC1270Q41023406-D4DDADA4-21BB-49A4-B6C0-132A74955F69Q43252991-F17949F3-43CC-425C-87F2-08E78FE70670Q43992402-21F86979-E236-4F38-9E7D-96701ADA7053Q47098092-0CCA34B4-3835-42C1-88EE-59BF1570AECFQ50420224-92F235C8-D644-4789-83DB-091C3B4854EEQ50857260-163C7F1C-21DA-4EA1-BF9B-F3C65C6A3F56Q51505865-47683EAF-8E35-4FCD-80CD-6398DDDDC6F1Q53167841-30D3F23E-09DD-4DA9-80BF-904658A6B124Q54977284-0C14617B-116B-4BF7-B65F-9E54AB6DE4FFQ64238834-D8F797C2-B719-41FA-991D-BD65AF351396Q73656453-8844694B-D77C-445C-AD68-276B06B120D0Q74418085-C88FA807-38B1-4286-BA2D-6C0C291791D1Q79819657-9E07C144-CDAB-4118-B293-18CC423ABA69Q80336010-957D5588-967D-4C4E-99F1-DB221450DD36Q83462964-49E76F75-EFF2-48F5-9DD9-5A7D06566C7CQ84036515-4BEDA11F-CEF8-4B75-8577-AEA31EFBE1CFQ89440701-82543BF3-27F9-4E59-874D-BBAD2B2EDD9EQ89503453-0F466A6B-62B6-4ECE-A2E8-DADC53FE4F9CQ90618624-9A29BB25-421A-4490-9031-98E424BEB434Q91993583-346A811C-2CAD-4921-BD81-BE5ABAAB735EQ92372211-8EF26FA5-0339-4428-8A3E-B6CC4F8C6213Q92725492-5BD19684-49E9-4AC5-8B45-547F71CE1044Q92725522-5A8C3F80-5E60-416E-8DB3-118AE354513FQ92792577-8F0295FA-9078-4480-8FE6-DA808B109827Q93219207-BBF7F445-B489-40CB-A388-9EA10C9C88D6Q96576905-1A7C52D0-9BAD-4A15-85D8-C119A0268012Q96586146-17236E0F-DC95-4C97-8237-C374C1ED81AD
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Marek Ussowicz
@ast
Marek Ussowicz
@en
Marek Ussowicz
@es
Marek Ussowicz
@nl
Marek Ussowicz
@pl
type
label
Marek Ussowicz
@ast
Marek Ussowicz
@en
Marek Ussowicz
@es
Marek Ussowicz
@nl
Marek Ussowicz
@pl
prefLabel
Marek Ussowicz
@ast
Marek Ussowicz
@en
Marek Ussowicz
@es
Marek Ussowicz
@nl
Marek Ussowicz
@pl
P214
P106
P1153
6506720238
P214
P31
P3124
P496
0000-0001-5725-4835
P735
P7859
viaf-162348677